Only one of six mice (17%) in each group treated with the Neuro-IL2/IL12 vaccine or the AJ-IL2/IL12 vaccine developed a tumour (Figure 1) and the other five in each group (83%) remained tumour free for over 40 days, a significant improvement over controls (P<0.01). This evidence concerns the gene IL2 and neoplasm.